Hepatic encephalopathy after the administration of the somatostatin analogue lanreotide;Encephalopathie hepatique apres injection de lanreotide, analogue de la somatostatine

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 11, 1996, Pages 1014-1016

  Robin, Edith ^a   Lebrec, Didier ^b   Hammel, Pascal ^a   Bernades, Pierre ^a   Ruszniewski, Philippe ^a,c  

^a Serv Gastroenterol   (France)

^b Service d'Hépatologie HÔpital Beaujon   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

hepatic encephalopathy; pancreatic endocrine tumor; portal vein thrombosis; somatostatin analogue

Indexed keywords

AMMONIA; ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

AGED; ARTICLE; CASE REPORT; ELECTROENCEPHALOGRAM; ENDOCRINE TUMOR; HEPATIC ENCEPHALOPATHY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER BLOOD FLOW; LIVER METASTASIS; MALE; PANCREAS TUMOR; CHEMICALLY INDUCED DISORDER; LIVER CIRCULATION; PATHOPHYSIOLOGY;

AGED; ANTINEOPLASTIC AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; INJECTIONS, INTRAMUSCULAR; LIVER CIRCULATION; MALE; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 0030347192     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bakti G, Fisch H, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiarepines: model experiments with triazolam. Hepatology 1987;7:629-38.
2. Ruszniewski P, Lehy T, Reyl-Desmars F, Le Roux S, Lewin M. Octreotide (SMS 201-995) inhibits the growth of colon peritoneal carcinomatosis in BDIX rats. Regul Pept 1993;43:141-7.
3. Saltz L, Trochanowski B, Buckley M, Hefferman B, Niedzwiecki D, Tao Yet al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-8.
4. Ruszniewski P, Rougier P, Rampai P, Grangé J.D, Jian R, Treffot MJ et al. Le lanréotide influence-t-il la croissance des métastases des tumeurs carcinoïdes ? (abstract). Gastroenterol Clin Biol 1994;18:A150.
5. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic haernodynamics in patients with cirrhosis of the liver. Comparison with vasopressin. Gastroenterology 1981;80:518-25.
6. Pringle SD, Mckee RF, Garden OJ, Lorimer AR, Carter DC. The effect of long acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1988;2:451-9.
7. Lebrec D, Bataille C, Bercoff E, Valla D. Hemodynamic changes in patients with portal venous obstruction. Hepatology 1983;3:550-3.
8. Cerini R, Lee S, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988;94:703-6.
9. McCormick PA, Chin J, Greenslade L, Karatapanis S, Dick R, McIntyre N et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995;21:1255-60.
10. Gaudin C, Moreau R, Champigneulle B, Soubrane O, Kleber G, Lebrec D. Short-term cardiovascular effects of somatostatin in patients with cirrhosis. Liver 1995;15:236-41.
11. Dudley J. Somatostatin and portal hypertensive bleeding: a safe therapeutic alternative ? Gastroenterology 1992;103:1973-7.
12. Trevisani F, Bernardi M, De Palma R, Servadei D, Piazzi S, Capelli M et al. Effects of somatostatin on plasma ammonia and amino acid profile during fasting and after protein feeding in cirrhotic patients. Hepatogastroenterology 1986;33:56-60.
13. Nomura F, Ohnishi K, Terabayashi H, Nakai T, Isobe K, Takekoshi K et al. Effect of intrahepatic portal-systemic shunting on hepatic ammonia extraction in patients with cirrhosis. Hepatology 1994;20:1478-81.